Skip to content

Drug interactions

Epcoritamab + Rasagiline

Severity: Minor

Epcoritamab and Rasagiline: minor interaction.

Last updated

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Epcoritamab induces cytokine release that can transiently suppress CYP enzymes. Rasagiline is mainly metabolized by CYP1A2, so its exposure may increase during cytokine release.

What this interaction means in plain words

Epcoritamab and Rasagiline have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.

Epcoritamab belongs to Oncology; Rasagiline belongs to Central Nervous System.

Evidence level: Low

Why it happens

Cytokine-mediated suppression of CYP activity, particularly CYP1A2, reducing rasagiline clearance.

What to do

Monitor for rasagiline adverse effects during the first weeks of epcoritamab and around cytokine release episodes.

What to ask your pharmacist

  • Is there anything I should notice while taking both?
  • Do I need to tell my doctor at the next visit?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Epcoritamab and Rasagiline, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 7 days on the web. No card needed.

Frequently asked questions

Can I take Epcoritamab with Rasagiline?

MediHelp rates the interaction as minor. Epcoritamab and Rasagiline have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Epcoritamab induces cytokine release that can transiently suppress CYP enzymes. Rasagiline is mainly metabolized by CYP1A2, so its exposure may increase during cytokine release.

How serious is the interaction between Epcoritamab and Rasagiline?

MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor for rasagiline adverse effects during the first weeks of epcoritamab and around cytokine release episodes.

What other medicines interact with Rasagiline?

MediHelp also lists interactions of Rasagiline with, for example, Atomoxetine, Brimonidine, Bupropion-naltrexone. The full list is on the Rasagiline page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in